We have known for over a century that cancer cells often have chromosome numbers that deviate strongly from the healthy diploid karyotype. The German pathologist David Hansemann already noted back in 1890 that, even within a given tumour, some nuclei contain more chromatin than others [1] . We now know that this phenotype of chromosomal instability (CIN) can be found in many cancer types and is particularly abundant in solid tumours. CIN tumours are notoriously difficult to treat with anti-cancer drugs. The continuous gain and loss of chromosomes in these tumour cells is thought to be the driver for intra-tumour heterogeneity. This unstable karyotype facilitates the accelerated evolution of cancer cells such that they can easily adapt to evade the action of chemotherapeutic agents [2] .
CIN is caused by errors in the segregation of chromosomes in mitosis. Chromosome segregation is controlled by an intricate cellular network, which ensures that each of the daughter cells inherits a complete copy of the genome. A key aspect of this network is sister chromatid cohesion, which is mediated by the cohesin complex. Cohesin is believed to entrap both sister chromatids of each individual chromosome inside its ring-shaped structure. Cohesin holds together the sister chromatids until the moment that all chromosomes are correctly attached to microtubules from both poles of the cell. Then the sudden destruction of cohesin allows the synchronous separation of the sister chromatids to the opposite poles. This process is tightly controlled, as premature loss of cohesion leads to segregation errors and to daughter cells with unequal karyotypes [3] .
It is therefore perhaps not surprising that the cohesin complex is often found to be mutated in CIN tumours [4] . An important example is the finding that mutations in cohesin's STAG2 subunit are causative for the CIN phenotype of glioblastoma cells [5] . Cohesion is also affected by inactivation of the pRB tumour suppressor pathway. pRB inactivation leads to defects in sister chromatid cohesion and to segregation errors in mitosis, which in turn cause chromosomal instability [6, 7] . Loss of pRB or its upstream regulator p16 ink4a is a common feature of many human cancers [8] . pRB inactivation may thereby represent a common cause of CIN in a large portion of human cancers.
The CIN phenotype of tumours in essence creates two therapeutic possibilities. The first option is to augment the chromosome segregation defect such that the degree of the errors is no longer compatible with survival of the cancer cells. A potential drawback of this approach is that healthy cells will likely undergo segregation defects due to this treatment, which is dangerous by itself. A fundamentally different approach is to correct the segregation defects of CIN tumours. This treatment will not kill cancer cells directly, but it would slow down intra-tumour evolution. This could be beneficial to prevent the development of resistance to chemotherapeutic agents.
An important new study from the Dyson laboratory [9] now shows that the segregation errors caused by pRB inactivation can be corrected by boosting sister chromatid cohesion. How pRB regulates cohesion is not fully understood, but it appears to involve the Suv4-20H2 methyltransferase. pRB binds to this factor that is important for the recruitment of cohesin to heterochromatin [10, 11] . Indeed, the segregation errors of pRB-deficient cells can be corrected by overexpression of Suv4-20H2. Importantly, the cohesion defect and the segregation errors can also be corrected by inactivation of cohesin's antagonist Wapl [9] . In the absence of Wapl, cohesin rings more stably associate with DNA [12] . The new paper goes on to show that inactivation of Wapl even corrects the chromosomal instability of non-small cell lung cancer cells in which the pRB pathway is compromised by either loss of pRB or loss of p16 ink4a , or by CDK4 amplification (Figure 1 ) [9] . This is a crucial finding that may have major consequences. If it were possible to stabilise the karyotype within CIN tumours, this would indeed be very valuable and this paper suggests that targeting Wapl might be one way to achieve this feat.
The new study interestingly also touches upon a current topic of debate [13] [14] [15] . Ultimately, CIN is the consequence of incorrect separation of chromosomes in mitosis, but this defect does not necessarily need to be caused by faults in the chromosome segregation machinery. In fact, CIN was recently shown to often be the consequence of errors in DNA replication [13] . Many cancer cells suffer from a decrease in replication speed that is referred to as 'replication stress'. This can lead to DNA segments that remain unreplicated, even though the cells progress from S phase to mitosis. Unreplicated DNA fragments in turn can cause segregation errors, as both chromatids of one chromosome stay connected by one stretch of DNA. The CIN phenotype can therefore be the consequence of either defects in S phase or errors in mitosis.
Replication stress can be caused by nucleotide insufficiency as a consequence of unscheduled S phase entry. In correspondence with earlier work, the new paper shows that pRB inactivation leads to such replication stress, and that this defect can be rescued by supplementing the cells with exogenous nucleosides [9, 16] . Unexpectedly, however, nucleoside addition also rescues the cohesion defect and the segregation errors of pRB-deficient cells. Perhaps even more remarkably, the replication stress of pRB-deficient cells is also rescued by the depletion of Wapl [9] . Inactivation of Wapl apparently rescues both the cohesion defects and the replication defects that are observed upon pRB inactivation.
These findings raise many questions on the precise mechanisms involved. How Wapl may affect DNA replication is unknown. This activity does appear to be conserved through evolution, as a recent paper has shown that Wapl-deficient budding yeast also display an increase in replication speed [17] . It will also be important to further dissect whether the replication stress is a consequence of the cohesion defect, or vice versa. Cohesin stably holds together the sister DNAs of each chromosome from S phase until mitosis. This paper underscores how poorly we actually understand the interconnections between DNA replication and the establishment of cohesion. But irrespective of the mechanism, this paper suggests that both nucleoside supplementation and Wapl inactivation might be valid approaches to correct the CIN phenotype of pRB-deficient tumours. Nucleoside supplementation may carry significant risk, as elevated dNTP levels can lead to increased cellular mutation rates [18] . Targeting Wapl for anti-cancer therapy may also not be without risk, as Wapl inactivation in healthy cells causes segregation defects by itself. However, Wapl depletion causes a p53-dependent cell-cycle arrest in non-cancerous cells, which should protect healthy cells against the adverse consequences of Wapl inactivation. Wapl loss in healthy cells leads to unwanted cohesin on chromosome arms in mitosis, whereas its inactivation in pRB-deficient cells appears to restore cohesion levels to a basal state that is optimal for proper chromosome segregation [9, 19, 20] .
Wapl has no known enzymatic activity, so it will not be straightforward to target Wapl with a drug. Also, how Wapl antagonises cohesin complexes is largely a mystery. It will therefore be important to further elucidate the cellular pathways by which Wapl regulates cohesion in order to uncover other players in this pathway that may be better drug targets. Such a drug could be highly beneficial as adjuvant therapy to prevent the resistance of CIN tumours to a primary drug that specifically targets the cancer cells.
We have learned a lot about chromosomal instability since Hansemann's pioneering work of the 1890s. This new paper [9] Recent reports have identified committed innate lymphoid cell (ILC) precursors and tissue-resident ILC subsets that have unique functional attributes. Taken together, these studies provide a framework for understanding how distinct ILCs are generated during hematopoiesis and further suggest additional parallels between models of ILC and T helper cell differentiation.
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